Murillo de Oliveira Antunes

Murillo de Oliveira Antunes

Auto-generated profile, based on publicly available information

Murillo de Oliveira Antunes

Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brasil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
PFPedro Freitas
Pedro Freitas
AFAntónio Ferreira
António Ferreira
EAEdmundo Arteaga-Fernández
Edmundo Arteaga-Fernández
MAMurrilo de Oliveira Antunes
Murrilo de Oliveira Antunes
JMJoão Mesquita
João Mesquita
CRCarlos Eduardo Rochitte
Carlos Eduardo Rochitte
Identifying the patients with hypertrophic cardiomyopathy (HCM) in whom the risk of sudden cardiac death (SCD) justifies the implantation of a cardioverter-defibrillator (ICD) in primary prevention remains challenging. Different risk stratification and criteria are used by the European and American guidelines in this setting. We sought to evaluate the role of cardiovascular magnetic resonance (CMR) late gadolinium enhancement (LGE) in improving these risk stratification strategies. We conducted a multicentric retrospective analysis of HCM patients who underwent CMR for diagnostic confirmation and/or risk stratification. Eligibility for ICD was assessed according to the HCM Risk-SCD score and the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) algorithm. The amount of LGE was quantified (LGE%) and categorized as 0%, 0.1–10%, 10.1–19.9% and ≥ 20%. The primary endpoint was a composite of SCD, aborted SCD, sustained ventricular tachycardia (VT), or appropriate ICD discharge. A total of 493 patients were available for analysis (58% male, median age 46 years). LGE was present in 79% of patients, with a median LGE% of 2.9% (IQR 0.4–8.4%). The concordance between risk assessment by the HCM Risk-SCD, ACCF/AHA and LGE was relatively weak. During a median follow-up of 3.4 years (IQR 1.5–6.8 years), 23 patients experienced an event (12 SCDs, 6 appropriate ICD discharges and 5 sustained VTs). The amount of LGE was the only independent predictor of outcome (adjusted HR: 1.08; 95% CI: 1.04–1.12; p < 0.001) after adjustment for the HCM Risk-SCD and ACCF/AHA criteria. The amount of LGE showed greater discriminative power (C-statistic 0.84; 95% CI: 0.76–0.91) than the ACCF/AHA (C-statistic 0.61; 95% CI: 0.49–0.72; p for comparison < 0.001) and the HCM Risk-SCD (C-statistic 0.68; 95% CI: 0.59–0.78; p for comparison = 0.006). LGE was able to increase the discriminative power of the ACCF/AHA and HCM Risk-SCD criteria, with net reclassification improvements of 0.36 (p = 0.021) and 0.43 (p = 0.011), respectively. The amount of LGE seems to outperform the HCM Risk-SCD score and the ACCF/AHA algorithm in the identification of HCM patients at increased risk of SCD and reclassifies a relevant proportion of patients.

1 May 2010 in Chest
Verified
Journal Article
Closed access
RPRodrigo P. Pedrosa
Rodrigo P. Pedrosa
LDLuciano F. Drager
Luciano F. Drager
PGPedro R. Genta
Pedro R. Genta
AAAline C.S. Amaro
Aline C.S. Amaro
MAMurillo O. Antunes
Murillo O. Antunes
GLGeraldo Lorenzi-Filho
Geraldo Lorenzi-Filho

1 October 2013 in American Heart Journal
Verified
Journal Article
Closed access
JMJulia Daher Carneiro Marsiglia
Julia Daher Carneiro Marsiglia
FCFlávia Laghi Credidio
Flávia Laghi Credidio
TOThéo Gremen Mimary de Oliveira
Théo Gremen Mimary de Oliveira
RRRafael Ferreira Reis
Rafael Ferreira Reis
MAMurillo de Oliveira Antunes
Murillo de Oliveira Antunes
APAlexandre da Costa Pereira
Alexandre da Costa Pereira

18 November 2024 in JACC
Verified
Journal Article
Open access
MKMikhail N. Kosiborod
Mikhail N. Kosiborod
DCDavid Z.I. Cherney
David Z.I. Cherney
ADAkshay S. Desai
Akshay S. Desai
JTJeffrey M. Testani
Jeffrey M. Testani
SVSubodh Verma
Subodh Verma
MPMark C. Petrie
Mark C. Petrie
Mineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused in clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for the suboptimal use of MRA. We evaluated the effects of sodium zirconium cyclosilicate (SZC) in optimizing use of spironolactone among participants with HFrEF and hyperkalemia. REALIZE-K (NCT04676646) was a prospective, double-blind, randomized- withdrawal trial in participants with HFrEF (NYHA II-IV; left ventricular ejection fraction ≤40%), optimal guideline-directed therapy (except MRA), and prevalent or incident MRA- induced hyperkalemia. During open-label run-in, participants underwent spironolactone titration (target: 50 mg/daily); those with hyperkalemia started SZC. Participants with normokalemia (potassium 3.5-5.0 mEq/L) on SZC and spironolactone ≥25 mg/daily were randomized to continued SZC or placebo for 6 months. The primary endpoint was optimal treatment response (normokalemia on spironolactone ≥25 mg/daily without rescue therapy for hyperkalemia [months 1-6]). The five key secondary endpoints were tested hierarchically. Exploratory endpoints included a composite of adjudicated cardiovascular death or worsening HF events (hospitalizations and urgent visits). Overall, 203 participants were randomized (SZC 102, placebo 101). Higher percentage of SZC- versus placebo-treated participants had optimal response (71% vs 36%; OR 4.45 [95% CI 2.89-6.86]; p<0.001). SZC (versus placebo) improved the first four key secondary endpoints: normokalemia on randomization dose of spironolactone and without rescue therapy (58% vs 23%; OR 4.58 [2.78-7.55]; p<0.001), receiving spironolactone ≥25 mg/daily (81% vs 50%; OR 4.33 [2.50-7.52]; p<0.001), time to hyperkalemia (HR 0.51 [0.37-0.71]; p<0.001), time to decrease/discontinuation of spironolactone due to hyperkalemia (HR 0.37 [0.17-0.73]; p=0.006). There was no between-group difference in KCCQ-CSS at 6 months (-1.01 points [-6.64-4.63]; p=0.72). Adverse events (64% vs 63%) and serious adverse events (23% vs 22%) were balanced between SZC and placebo, respectively. Composite of CV death or worsening HF occurred in 11 (11%) participants in the SZC group (1 with CV death, 10 with HF events) and 3 (3%) participants in the placebo group (1 with CV death, 2 with HF events; log-rank nominal p=0.034). In participants with HFrEF and hyperkalemia, SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose, and reduced risk of hyperkalaemia and down-titration/discontinuation of spironolactone. Although underpowered for clinical outcomes, more participants had HF events with SZC than placebo, which should be factored into the clinical decision making.

8 December 2010 in Cardiology
Verified
Journal Article
Closed access
RPRodrigo P. Pedrosa
Rodrigo P. Pedrosa
SLSandro G. Lima
Sandro G. Lima
LDLuciano F. Drager
Luciano F. Drager
PGPedro R. Genta
Pedro R. Genta
AAAline C.S. Amaro
Aline C.S. Amaro
GLGeraldo Lorenzi-Filho
Geraldo Lorenzi-Filho
Objectives: To evaluate clinical predictors of poor sleep quality and quality of life (QOL) in patients with hypertrophic cardiomyopathy (HCM). Methods: Consecutive stable patients with HCM were evaluated for the risk of obstructive sleep apnea (OSA) by the Berlin Questionnaire, daytime sleepiness by the Epworth Sleepiness Scale, sleep quality by the Pittsburgh Sleep Questionnaire Index and QOL by the Minnesota Living with Heart Failure Questionnaire. Asymptomatic subjects without HCM were used as controls. Results: We studied 84 patients with HCM and 42 controls who were similar with regard to gender (49 vs. 50% males), age [52 (38–62) vs. 47 (33–58) years] and body mass index (27 ± 4 vs. 27 ± 5). HCM diagnosis, high risk for OSA and female gender were independently associated with poor sleep quality in the entire population. Among patients with HCM, poor QOL was independently associated with poor sleep quality, New York Heart Association functional class and diuretic therapy. Conclusion: Poor sleep quality is very common in patients with HCM and may have a negative impact on the QOL, which in turn is an important marker of prognosis in patients with cardiomyopathies.

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
FFFabio Fernandes
Fabio Fernandes
MSMarcus V. Simões
Marcus V. Simões
ECEdileide de Barros Correia
Edileide de Barros Correia
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
OCOtavio Rizzi Coelho-Filho
Otavio Rizzi Coelho-Filho
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...] 1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis